Recombinant human anti-PCSK9 monoclonal antibody (Salubris)

重组全人源抗PCSK9单克隆抗体（信立泰）

Report date: 2023/10/08 14:06:56

Base Information

Drug NameRecombinant human anti-PCSK9 monoclonal antibody (Salubris)
Drug Alias NameSAL003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaHyperlipidemiasDyslipidemias +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShenzhen Salubris Pharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Genemen Biotech Co LtdXinlitai (Chengdu) Biological Technology Co LtdShenzhen Salubris Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaHyperlipidemiasDyslipidemias +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A